Relay Therapeutics shares are trading higher after the company announced initial clinical data from the Phase 2 ReInspire trial of zovegalisib in vascular anomalies signaling the advantage of PI3Kα mutant-selective inhibition.

RLAY

<p>Relay Therapeutics shares are trading higher after the company announced initial clinical data from the Phase 2 ReInspire trial of zovegalisib in vascular anomalies signaling the advantage of PI3Kα mutant-selective inhibition.</p>

benzinga_article

Relay Therapeutics

Invesco Biotechnology & Genome ETF

VG Health

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

iShares Global Healthcare

ALPS Medical Breakthrough

News